{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T19:41:27Z","timestamp":1768592487451,"version":"3.49.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,12,3]],"date-time":"2024-12-03T00:00:00Z","timestamp":1733184000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,12,3]],"date-time":"2024-12-03T00:00:00Z","timestamp":1733184000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Salmoral A."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1007\/s00198-024-07309-9","type":"journal-article","created":{"date-parts":[[2024,12,3]],"date-time":"2024-12-03T03:59:05Z","timestamp":1733198345000},"page":"245-254","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Bisphosphonate drug holidays in osteoporosis according to fracture risk profile"],"prefix":"10.1007","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-8097-7846","authenticated-orcid":false,"given":"Asunci\u00f3n","family":"Salmoral","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Peris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"L\u00f3pez Medina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Fl\u00f3rez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Barcel\u00f3","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Pascual Pastor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Ros","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Grados","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Aguado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Gifre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Cerd\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F. J.","family":"Aguilar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Panero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Costa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Casado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Mart\u00ednez Ferrer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Gra\u00f1a","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Gua\u00f1abens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"for the OsteoResSer Working Group of the Spanish Society of Rheumatology","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,12,3]]},"reference":[{"key":"7309_CR1","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1016\/S0140-6736(96)07088-2","volume":"348","author":"DM Black","year":"1996","unstructured":"Black DM, Cummings SR, Karp DB, for the Fracture Intervention Trial Research Group et al (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 348:1535\u20131541","journal-title":"Lancet"},{"issue":"24","key":"7309_CR2","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1001\/jama.280.24.2077","volume":"280","author":"SR Cummings","year":"1998","unstructured":"Cummings SR, Black DM, Thompson DE, for the Fracture Intervention Trial Research Group et al (1998) Effect of Alendronate on Risk on Fracture in Women with low bone density but without vertebral Fractures. JAMA 280(24):2077\u20132082","journal-title":"JAMA"},{"key":"7309_CR3","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1056\/NEJMoa067312","volume":"356","author":"DM Black","year":"2007","unstructured":"Black DM, Delmas PD, Eastell R et al for the HORIZON Pivotal Fracture Trial (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356:1809\u20131822","journal-title":"N Engl J Med"},{"key":"7309_CR4","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.amjmed.2012.06.023","volume":"126","author":"M McClung","year":"2013","unstructured":"McClung M, Harris ST, Miller PD et al (2013) Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday. Am J Med 126:13\u201320","journal-title":"Am J Med"},{"issue":"2","key":"7309_CR5","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/8756-3282(95)00445-9","volume":"18","author":"JH Lin","year":"1996","unstructured":"Lin JH (1996) Bisphosphonates: a review of their pharmacokinetic properties. Bone 18(2):75\u201385","journal-title":"Bone"},{"key":"7309_CR6","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1007\/s00198-007-0540-8","volume":"19","author":"RGG Russell","year":"2008","unstructured":"Russell RGG, Watts NB, Ebetino FH, Rogers MJ (2008) Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int 19:733\u2013759","journal-title":"Osteoporos Int"},{"key":"7309_CR7","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1359\/jbmr.0707onj","volume":"22","author":"S Khosla","year":"2007","unstructured":"Khosla S, Burr D, Cauley J et al (2007) Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American society for bone and mineral research. J Bone Miner Res 22:1479\u20131491","journal-title":"J Bone Miner Res"},{"key":"7309_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/jbmr.1998","volume":"29","author":"E Shane","year":"2014","unstructured":"Shane E, Burr D, Abrahamsen B et al (2014) Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the american society for bone and mineral research. J Bone Miner Res 29:1\u201321","journal-title":"J Bone Miner Res"},{"issue":"1","key":"7309_CR9","doi-asserted-by":"publisher","first-page":"R29","DOI":"10.1530\/EJE-18-0282","volume":"180","author":"BL Langdahl","year":"2019","unstructured":"Langdahl BL (2019) Treatment breaks in long-term management of osteoporosis. Eur J Endocronol 180(1):R29\u2013R35","journal-title":"Eur J Endocronol"},{"issue":"24","key":"7309_CR10","doi-asserted-by":"publisher","first-page":"2927","DOI":"10.1001\/jama.296.24.2927","volume":"296","author":"DM Black","year":"2006","unstructured":"Black DM, Schwartz AV, Ensrud KE et al ; FLEX Research Group (2006) Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 296(24):2927\u201338","journal-title":"JAMA"},{"issue":"2","key":"7309_CR11","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1002\/jbmr.1494","volume":"27","author":"DM Black","year":"2012","unstructured":"Black DM, Reid IR, Boonen S et al (2012) The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res 27(2):243\u2013254","journal-title":"J Bone Miner Res"},{"issue":"1","key":"7309_CR12","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1002\/jbmr.2708","volume":"31","author":"RA Adler","year":"2016","unstructured":"Adler RA, El-Hajj Fuleihan G, Bauer DC et al (2016) Managing osteoporosis in patients on long-term bisphosphonate treatment: report of a task force of the American society for bone and mineral research. J Bone Miner Res 31(1):16\u201335","journal-title":"J Bone Miner Res"},{"issue":"6","key":"7309_CR13","first-page":"e10629","volume":"6","author":"M Wang","year":"2022","unstructured":"Wang M, Wu YF, Girgis CM (2022) Bisphosphonate drug holidays: evidence from clinical trials and real-world studies. J Bone Miner Res Plus 6(6):e10629","journal-title":"J Bone Miner Res Plus"},{"key":"7309_CR14","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.3390\/jcm10051140","volume":"10","author":"KN Hayes","year":"2021","unstructured":"Hayes KN, Winter EM, Cadarette SM, Burden AM (2021) Duration of bisphosphonate drug holidays in osteoporosis patients: a narrative review of the evidence and considerations for decision-making. J Clin Med 10:1140","journal-title":"J Clin Med"},{"issue":"4","key":"7309_CR15","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1016\/j.bone.2011.06.027","volume":"49","author":"P Peris","year":"2011","unstructured":"Peris P, Torra M, Olivares V et al (2011) Prolonged bisphosphonate release after treatment in women with osteoporosis. Relationship with bone turnover. Bone 49(4):706\u2013709","journal-title":"Bone"},{"issue":"5","key":"7309_CR16","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1002\/jbmr.3654","volume":"34","author":"TY Kim","year":"2019","unstructured":"Kim TY, Bauer DC, McNabb BL, Schafer AL, Cosman F, Black DM et al (2019) Comparison of BMD changes and bone formation marker levels 3 years after bisphosphonate discontinuation: FLEX and HORIZON-PFT extension I trials. J Bone Miner Res 34(5):810\u2013816","journal-title":"J Bone Miner Res"},{"key":"7309_CR17","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.bone.2013.09.023","volume":"58","author":"EF Eriksen","year":"2014","unstructured":"Eriksen EF, D\u00edez P\u00e9rez A, Boonen S (2014) Update on long-term treatment with bisphosphonates for postmenopausal osteoporosis: a systematic review. Bone 58:126\u2013135","journal-title":"Bone"},{"key":"7309_CR18","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.maturitas.2017.04.008","volume":"101","author":"P Anagnostis","year":"2017","unstructured":"Anagnostis P, Paschou SA, Mintziori G et al (2017) Drug holidays from bisphosphonates and denosumab in postmenopausal osteoporosis: EMAS position statement. Maturitas 101:23\u201330","journal-title":"Maturitas"},{"issue":"4","key":"7309_CR19","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1007\/s00198-018-04823-5","volume":"30","author":"KE Naylor","year":"2019","unstructured":"Naylor KE, McCloskey EV, Jacques RM et al (2019) Clinical utility of bone turnover markers in monitoring the withdrawal of treatment with oral bisphosphonates in postmenopausal osteoporosis. Osteoporos Int 30(4):917\u2013922","journal-title":"Osteoporos Int"},{"issue":"5","key":"7309_CR20","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1097\/MLR.0000000000001294","volume":"58","author":"JR Curtis","year":"2020","unstructured":"Curtis JR, Saag KJ, Arora T et al (2020) Duration of bisphosphonate drug holidays and associated fracture risk. Med Care 58(5):419\u2013426","journal-title":"Med Care"},{"issue":"4","key":"7309_CR21","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1007\/s00198-018-4791-3","volume":"30","author":"S Nayak","year":"2019","unstructured":"Nayak S, Greenspan SL (2019) A systematic review and meta-analysis of the effect of bisphosphonate drug holidays on bone mineral density and osteoporotic fracture risk. Osteoporos Int 30(4):705\u2013720","journal-title":"Osteoporos Int"},{"issue":"1","key":"7309_CR22","doi-asserted-by":"publisher","first-page":"13","DOI":"10.4321\/S1889-836X2022000100003","volume":"14","author":"JA Riancho","year":"2022","unstructured":"Riancho JA, Peris P, G\u00f3nzalez-Mac\u00edas J, P\u00e9rez Castrill\u00f3n JL, en nombre de la comisi\u00f3n de Redacci\u00f3n de las gu\u00edas de osteoporosis de la SEIOMM (2022) Gu\u00edas de pr\u00e1ctica cl\u00ednica en la osteoporosis posmenop\u00e1usica, glucocorticoidea y del var\u00f3n (actualizaci\u00f3n 2022). Rev Osteoporos Metab Miner 14(1):13\u201333","journal-title":"Rev Osteoporos Metab Miner"},{"issue":"12","key":"7309_CR23","doi-asserted-by":"publisher","first-page":"2769","DOI":"10.1007\/s00198-012-2093-8","volume":"23","author":"A Diez-Perez","year":"2012","unstructured":"Diez-Perez A, Adachi JD, Agnusdei D, IOF CSA Inadequate Responders Working Group et al (2012) Treatment failure in osteoporosis. Osteoporos Int 23(12):2769\u201374","journal-title":"Osteoporos Int"},{"issue":"12","key":"7309_CR24","doi-asserted-by":"publisher","first-page":"4546","DOI":"10.1210\/jc.2014-1971","volume":"99","author":"F Cosman","year":"2014","unstructured":"Cosman F, Cauley JA, Eastell R et al (2014) Reassessment of fracture risk in women after 3years of treatment with zoledronic acid: when is reasonable to discontinue treatment? J Clin Endocrinol Metab 99(12):4546\u20134554","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"7309_CR25","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1515\/cclm-2015-0162","volume":"54","author":"N Gua\u00f1abens","year":"2016","unstructured":"Gua\u00f1abens N, Filella X, Monegal A et al (2016) Lab Oscat Study Group. Reference intervals for bone turnover markers in Spanish premenopausal women. Clin Chem Lab Med 54(2):293\u2013303","journal-title":"Clin Chem Lab Med"},{"issue":"2","key":"7309_CR26","doi-asserted-by":"publisher","first-page":"163","DOI":"10.4158\/EP171975.OR","volume":"24","author":"B Bindon","year":"2018","unstructured":"Bindon B, Adams W, Balasubramanian N, Sandhu J, Camacho P (2018) Osteoporotic fractures during bisphosphonate drug holiday. Endocr Pract 24(2):163\u2013169","journal-title":"Endocr Pract"},{"key":"7309_CR27","doi-asserted-by":"publisher","first-page":"115431","DOI":"10.1016\/j.bone.2020.115431","volume":"138","author":"J Pfeilschifter","year":"2020","unstructured":"Pfeilschifter J, Steinebach I, Trampisch HJ, Rudolf H (2020) Bisphosphonate drug holidays: risk of fractures and mortality in a prospective cohort study. Bone 138:115431","journal-title":"Bone"},{"issue":"12","key":"7309_CR28","doi-asserted-by":"publisher","first-page":"3431","DOI":"10.1007\/s00198-017-4215-9","volume":"28","author":"MA Mignot","year":"2017","unstructured":"Mignot MA, Taisne N, Legroux I, Cortet B, Paccou J (2017) Bisphosphonate drug holidays in postmenopausal osteoporosis: effect on clinical fracture risk. Osteoporos Int 28(12):3431\u20133438","journal-title":"Osteoporos Int"},{"issue":"7","key":"7309_CR29","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1001\/jamainternmed.2014.1232","volume":"174","author":"DC Bauer","year":"2014","unstructured":"Bauer DC, Schwartz A, Palermo L et al (2014) Fracture prediction after discontinuation of 4 to 5 years of alendronate therapy: the FLEX study. JAMA Int Med 174(7):1126\u20131134","journal-title":"JAMA Int Med"},{"key":"7309_CR30","unstructured":"Curtis JR, Chen R, Li Z et al (2017) The impact of the duration of bisphosphonate drug holidays on hip fracture rates (abstract). Arthritis Rheumatol 69(Suppl 10). https:\/\/acrabstracts.org\/abstract\/the-impact-of-the-duration-of-bisphosphonate-drug-holidays-on-hip-fracture-rates.\u00a0Accessed 20 Nov 2024"},{"key":"7309_CR31","doi-asserted-by":"publisher","first-page":"335","DOI":"10.7326\/M21-2512","volume":"175","author":"KN Hayes","year":"2022","unstructured":"Hayes KN, Brown KA, Cheung AM, Kim SA, Juurlink DN, Cadarette SM (2022) Comparative fracture risk during osteoporosis drug holidays after long-term risedronate versus alendronate therapy a propensity score-matched cohort study. Ann Intern Med 175:335\u2013343","journal-title":"Ann Intern Med"},{"issue":"11","key":"7309_CR32","first-page":"2793","volume":"109","author":"MTY Leung","year":"2024","unstructured":"Leung MTY, Turner JP, Marquina C, llomaki J, Tran T, Bell JS (2024) Effect of Bisphosphonate drug holiday on mortality following hip fracture. J Clin Endocrinol Metab 109(11):2793\u20132801","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"7309_CR33","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1002\/jbmr.3420","volume":"33","author":"AL Adams","year":"2018","unstructured":"Adams AL, Adams JL, Raebel MA et al (2018) Bisphosphonate drug holiday and fracture risk: a population-based cohort study. J Bone Miner Res 33(7):1252\u20131259","journal-title":"J Bone Miner Res"},{"issue":"8","key":"7309_CR34","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1007\/s00198-021-05835-4","volume":"32","author":"AS Solling","year":"2021","unstructured":"Solling AS, Christensen DH, Darvalics B, Harslof T, Thomsen RW, Langdahl B (2021) Fracture rates in patients discontinuing alendronate treatment in real life: a population-based cohort study. Osteoporos Int 32(8):1557\u20131566","journal-title":"Osteoporos Int"},{"key":"7309_CR35","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s00198-007-0460-7","volume":"19","author":"NB Watts","year":"2008","unstructured":"Watts NB, Chines A, Olszynski WP et al (2008) Fracture risk remains reduced one year after discontinuation of risedronate. Osteoporos Int 19:365\u2013372","journal-title":"Osteoporos Int"},{"issue":"4","key":"7309_CR36","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1111\/cen.13012","volume":"84","author":"J Roberts","year":"2016","unstructured":"Roberts J, Castro C, Moore AEB, Fogelman I, Hampson G (2016) Changes in bone mineral density and bone turnover in patients on \u201cdrug holiday\u201d following bisphosphonate therapy: real-life clinic setting. Clin Endocrinol 84(4):509\u2013515","journal-title":"Clin Endocrinol"},{"key":"7309_CR37","doi-asserted-by":"publisher","first-page":"3367","DOI":"10.1210\/jc.2011-0412","volume":"96","author":"R Eastell","year":"2011","unstructured":"Eastell R, Hannon RA, Wenderoth D, Rodriguez-Moreno J, Sawicki A (2011) Effect of stopping risedronate after long-term treatment on bone turnover. J Clin Endocrinol Metab 96:3367\u20133373","journal-title":"J Clin Endocrinol Metab"},{"key":"7309_CR38","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1007\/s00198-015-3447-9","volume":"27","author":"LHR Xu","year":"2016","unstructured":"Xu LHR, Adams-Huet B, Poindexter JR, Maalouf NM (2016) Determinants of change in bone mineral density and fracture risk during bisphosphonate holiday. Osteoporos Int 27:1701\u20131708","journal-title":"Osteoporos Int"},{"issue":"1","key":"7309_CR39","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1002\/jbmr.4448","volume":"37","author":"J Banefelt","year":"2022","unstructured":"Banefelt J, Timoshanko J, S\u00f6reskog E et al (2022) Total hip bone mineral density as an indicator of fracture risk in bisphosphonate-treated patients in a real-world setting. J Bone Miner Res 37(1):52\u201358","journal-title":"J Bone Miner Res"},{"issue":"6","key":"7309_CR40","doi-asserted-by":"publisher","first-page":"989","DOI":"10.4158\/EP12425.OR","volume":"19","author":"M LE Chiha","year":"2013","unstructured":"LE Chiha M, Ball CA, Sinacore JM, Camacho PM (2013) Long-term follow-up of patients on drug holiday from bisphosphonate: real world setting. Endocr Pract 19(6):989\u2013994","journal-title":"Endocr Pract"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-024-07309-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00198-024-07309-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-024-07309-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T09:57:06Z","timestamp":1739440626000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00198-024-07309-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,3]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["7309"],"URL":"https:\/\/doi.org\/10.1007\/s00198-024-07309-9","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,3]]},"assertion":[{"value":"7 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"A. Salmoral has received fees for lectures, courses or congress registration from Theramex, Gedeon-Ritcher and Amgen.\u00a0P. Peris has received fees for lectures, consultant or congress registration from Amgen, UCB, FAES Pharma, Gedeon Richter Theramex y Rubi\u00f3. C. L\u00f3pez\u00a0Medina\u00a0has received honoraria as speaker fees\/consulting from Abbvie, Janssen, Lilly, MSD, Novartis, Pfizer and UCB.\u00a0I. Ros has received fees for lectures or courses from Amgen, UCB and Theramex.\u00a0P. Aguado has received fees for lectures and\/or advice from Abbie, Alexion, Amgen, Astra Zeneca, Eli Lilly, Faes, Gedeon-Richter, GP Pharm, Kyowa Kirin, MSD, Rubi\u00f3 and Theramex. S. Garcia has received fees for lectures or congress registration from Amgen, UCB, Gedeon Richter, Lilly, Abbvie, Gr\u00fcnenthal pharma, Italfarmaco and GP-pharm. L. Gifre declares receipt of lecture fees or congress registration from UCB, Amgen, Rubi\u00f3, Stada, Theramex, Lilly, Abbie, Astellas, Kyowa Kyrin and Gebro. D. Cerd\u00e1 has received fees for lectures, consultant or congress registration from Amgen, UCB, Lilly, Gebro, Italf\u00e1rmaco and Abbvie. F. J. Aguilar has received fees for lectures, consultant, editor and congress registration from Amgen, UCB, FAES Pharma, Gebro, Gedeon Richter, Theramex and Asacpharma. E. Costa has received congress funding from Rubi\u00f3,\u00a0Amgen and Kyowa-kirin. E. Casado has received fees for conferences and consultancies from Amgen, UCB, Theramex, STADA, Italfarmaco, FAES, Gedeon-Richter, GP-Pharm and Rubi\u00f3; and has received congress funding from UCB, Amgen, Rubi\u00f3 and Theramex. A. Mart\u00ednez-Ferrer has received fees for lectures or congress registration from Amgen, UCB, Gedeon Richter, Theramex and STADA. J. Gra\u00f1a has received fees for lectures, consultant or congress registration from Amgen, UCB, FAES Pharma, Gebro, Gedeon Richter and Theramex.\u00a0N. Gua\u00f1abens has received honoraria for advisory boards or lectures from Amgen, Eli Lilly, Theramex, Gedeon Richter and UCB.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}